Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

Background: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. Well-established drugs used for MS patients after the first demyelinating event in the Czech Republic include glatiramer acetate (GA), interferon beta-1a (IFNβ-1a), IFN beta-1b...

Full description

Bibliographic Details
Main Authors: Zbyšek Pavelek, Lukáš Sobíšek, Jana Šarláková, Pavel Potužník, Marek Peterka, Ivana Štětkárová, Pavel Štourač, Jan Mareš, Pavel Hradílek, Radek Ampapa, Markéta Grünermelová, Marta Vachová, Eva Recmanová, Francesco Angelucci, Simona Halúsková, Martin Vališ
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
treatment
long-term therapy
clinical practice
DMD
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2020.593527/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2020.593527/full

Similar Items